MSc Student of Hematology & Blood Banking, Mashhad University of Medical Sciences , Mashhad, Iran.
Central Diagnostic Laboratories, Ghaem Hospital, Mashhad University of Medical Sciences , Mashhad, Iran.
Expert Rev Hematol. 2020 Nov;13(11):1265-1275. doi: 10.1080/17474086.2020.1831383. Epub 2020 Oct 12.
COVID-19 disease has spread worldwide from December 2019 to the present day; the early stage of this disease can be associated with high D-dimer, prolonged PT, and elevated levels of fibrinogen, indicating activation of coagulation pathways and thrombosis. In this article, we analyze the levels of D-dimer in patients with COVID-19.
In the current study, three databases, PubMed, Scopus, Web of Science, searched using related keywords and information extracted from articles such as location, sample size, gender, age, coagulation test values, patient results, and disease severity.
D-dimer level is one of the measures used in patients to detect thrombosis. Studies have reported an increase in D-dimer and fibrinogen concentrations in the early stages of COVID-19 disease a 3 to 4-fold rise in D-dimer levels is linked to poor prognosis. In addition, underlying diseases such as diabetes, cancer, stroke, and pregnancy may trigger an increase in D-dimer levels in COVID-19 patients. Measuring the level of D-dimer and coagulation parameters from the early stage of the disease can also be useful in controlling and managing of COVID-19 disease.
COVID-19 疾病自 2019 年 12 月以来在全球范围内传播;该疾病的早期阶段可能与高 D-二聚体、PT 延长和纤维蛋白原水平升高有关,表明凝血途径和血栓形成的激活。在本文中,我们分析了 COVID-19 患者的 D-二聚体水平。
在目前的研究中,使用相关关键词在三个数据库,即 PubMed、Scopus、Web of Science 中进行搜索,并从文章中提取了位置、样本量、性别、年龄、凝血试验值、患者结果和疾病严重程度等信息。
D-二聚体水平是用于检测血栓形成的患者的一种测量方法。研究表明,在 COVID-19 疾病的早期阶段,D-二聚体和纤维蛋白原浓度增加,D-二聚体水平升高 3-4 倍与预后不良有关。此外,糖尿病、癌症、中风和妊娠等基础疾病可能会导致 COVID-19 患者的 D-二聚体水平升高。从疾病的早期阶段测量 D-二聚体和凝血参数的水平也有助于控制和管理 COVID-19 疾病。